LBL-015 is an anti-programmed death receptor-1 (PD-1) antibody-transforming growth factor beta receptor 2 (TGF-βR2) bifunctional antibody fusion protein.LBL-015 can simultaneously block PD-1/PD-L1 and TGF-β/TGF-βR2 signaling pathways, improve immunosuppression, and enhance immune response.In addition, LBL-015 can block TGF-β in the tumor microenvironment, further improving immune cell response and inhibiting tumor metastasis.On February 8, 2021 and July 1, 2021, the FDA and NMPA clinical approval documents were obtained respectively.Currently, LBL-015 single-drug clinical research is in phase I/II phase.The indications for LBL-015 to be developed include hematological tumors and solid tumors.
Weilizhibo owns all the rights of LBL-015 worldwide.
LBL-019 is a monoclonal antibody targeting tumor necrosis factor receptor-2 (TNFR2).LBL-019 can specifically bind to TNFR2, block the combination of TNFR2 and TNFα, and enhance the activity of immune cells through immune regulation to achieve anti-tumor effects.On December 10, 2021 and December 17, 2021, the NMPA and FDA clinical approval documents were obtained respectively.Currently, LBL-019 single-drug clinical research is in phase I/II phase.LBL-019 is intended to be developed for indications including hematological tumors and solid tumors.
Weilizhibo owns all the rights of LBL-019 worldwide.
LBL-024 is a bispecific antibody consisting of anti-programmed death-ligand-1 (PD-L1) and anti-4-1BB (CD137) antibodies.LBL-024 blocks the immunosuppressive pathway by targeting PD-L1, and effectively gathers and activates 4-1BB to play an important co-stimulatory role, thereby activating T cells to exert a strong immune effect and achieve the purpose of anti-tumor.The LBL-024 project was approved by the FDA and NMPA for clinical approval on July 30, 2021 and September 9, 2021, respectively.Currently, LBL-024 single-drug clinical research is in phase I/II phase.LBL-024 is intended to be developed for indications including hematological tumors and solid tumors.
Weilizhibo owns all rights of LBL-024 worldwide.